6 results about "Reference drug" patented technology

The present application relates to the technical field of healthcare informatics, and particularly relates to an intelligent drug clinical trial scheme generation method and system, comprising: receiving multi-source data of a candidate molecule and performing standardization processing to obtain a standardized data set; retrieving associated literature based on the standardized data set to obtain a target point evidence quality report; retrieving measured data of a reference drug of the same target point based on the standardized data set to obtain a composite prediction data structure; taking the credibility label in the target point evidence quality report and the composite prediction data structure as an explicit constraint to generate a clinical trial parameter of the candidate molecule and obtain a preliminary phase I clinical trial scheme; and performing comprehensive feasibility scoring on the phase I clinical trial scheme to output a final intelligent drug clinical trial scheme. The present application makes the clinical parameters have traceable information quality basis, and the generated trial scheme carries a confidence level classification description, which is helpful to improve the transparency and checkability of clinical development decisions.

Examples of assessing susceptibility of a target pathogen based on autofluorescence, are described. In an example, a sample containing a target pathogen and a predefined concentration of a target drug may be obtained. Thereafter, autofluorescence features based on autofluorescence exhibited by the sample in response to the sample being subjected to excitation radiation, may be determined. Once the autofluorescence features are determined, they may be analyzed based on a susceptibility-detection model to determine susceptibility of the target pathogen with respect to the target drug. In an example, the susceptibility-detection model is trained based on a training autofluorescence features correlated with reference data, in which the reference data includes information pertaining to susceptibility or resistance of a reference pathogen with respect to a reference drug.

To identify the type of drug and improve the accuracy of that identification. [Solution] The computer (60) includes a feature extraction unit (64a) that extracts information from an captured image (82) indicating the reflection region of light irradiated onto the target drug, and a comparison unit (64b) that compares the information extracted by the feature extraction unit 64a with information indicating the reflection region of light irradiated onto a reference drug, and determines the type of target drug based on the result of the comparison.

The invention relates to the field of medical biology, in particular to a fermentation basal culture medium which comprises 0.04-0.2 mu M of copper ions, 1.12 mM of methionine and 0.04 mM of EDTA (Ethylene Diamine Tetraacetic Acid). The invention also discloses an application of the culture medium in reducing the C-terminal amidation of the monoclonal antibody and a method for reducing the C-terminal amidation of the monoclonal antibody. The method comprises the step of inoculating cells capable of secreting and expressing the antibody into the culture medium for fermentation culture. By using the culture medium and the method, the C-terminal amidation level of the IgG4 monoclonal antibody can be remarkably reduced under the condition of not generating negative effects on cell growth metabolism and antibody yield, other quality attributes (antibody purity, acid isomer and glycoform) are kept to be comparable with a reference drug, and the culture medium and the method are suitable for industrial large-scale production.

The invention relates to the technical field of biological medicine, in particular to application of troxerutin in preparation of a medicine for improving dyslipidemia. According to the application disclosed by the invention, in a streptozotocin-induced type 2 diabetes rat model, the intervention of troxerutin for seven weeks generates a remarkable and dose-dependent improvement effect, and the effect of troxerutin reaches a level which can be compared with or even better than that of a reference drug metformin (10 mg / kg / day). And the troxerutin is derived from a natural plant, the water-soluble characteristic of the troxerutin is beneficial to absorption and metabolism, and no obvious adverse reaction is observed in the experimental period of the invention, which indicates that the troxerutin has better safety than many synthetic drugs.

The invention relates to the technical field of medical care informatics, in particular to an intelligent drug clinical test scheme generation method and system.The method comprises the steps that multi-source data of candidate molecules is received and subjected to standardization processing, and a standardized data set is obtained; retrieving the associated literature based on the standardized data set to obtain a target evidence quality report; retrieving measured data of the same-target reference drug based on the standardized data set to obtain a composite prediction data structure; taking the target evidence quality report and the credibility label in the composite prediction data structure as explicit constraints, generating clinical test parameters of candidate molecules, and obtaining a preliminary I-stage clinical test scheme; and performing comprehensive feasibility scoring on the I-stage clinical test scheme, and outputting a final intelligent drug clinical test scheme. According to the method, the clinical parameters have traceable information quality basis, the generated test scheme carries confidence level description, and the transparency and the verifiability of clinical development decisions can be improved.